Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
DIVIS LABORATORIES TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DIVIS LABORATORIES Mar-23 |
TEVA PHARMA Dec-13 |
DIVIS LABORATORIES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 4,641 | 3,481 | - | |
Low | Rs | 2,730 | 3,024 | - | |
Sales per share (Unadj.) | Rs | 292.6 | 1,997.6 | - | |
Earnings per share (Unadj.) | Rs | 68.7 | 124.8 | - | |
Cash flow per share (Unadj.) | Rs | 81.6 | 286.3 | - | |
Dividends per share (Unadj.) | Rs | 30.00 | 109.24 | - | |
Avg Dividend yield | % | 0.8 | 3.4 | 24.2% | |
Book value per share (Unadj.) | Rs | 480.9 | 2,219.0 | - | |
Shares outstanding (eoy) | m | 265.47 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 12.6 | 1.6 | 773.7% | |
Avg P/E ratio | x | 53.7 | 26.1 | 205.9% | |
P/CF ratio (eoy) | x | 45.2 | 11.4 | 397.5% | |
Price / Book Value ratio | x | 7.7 | 1.5 | 522.9% | |
Dividend payout | % | 43.7 | 87.5 | 49.9% | |
Avg Mkt Cap | Rs m | 978,378 | 2,757,874 | 35.5% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 9,750 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,690.2 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,354.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 77,675 | 1,693,984 | 4.6% | |
Other income | Rs m | 3,447 | 0 | - | |
Total revenues | Rs m | 81,122 | 1,693,984 | 4.8% | |
Gross profit | Rs m | 23,691 | 463,899 | 5.1% | |
Depreciation | Rs m | 3,432 | 136,926 | 2.5% | |
Interest | Rs m | 20 | 33,273 | 0.1% | |
Profit before tax | Rs m | 23,686 | 293,700 | 8.1% | |
Minority Interest | Rs m | 0 | 1,334 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,798 | -0.0% | |
Tax | Rs m | 5,453 | -3,586 | -152.1% | |
Profit after tax | Rs m | 18,234 | 105,822 | 17.2% | |
Gross profit margin | % | 30.5 | 27.4 | 111.4% | |
Effective tax rate | % | 23.0 | -1.2 | -1,885.5% | |
Net profit margin | % | 23.5 | 6.2 | 375.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 97,437 | 1,144,111 | 8.5% | |
Current liabilities | Rs m | 15,331 | 997,761 | 1.5% | |
Net working cap to sales | % | 105.7 | 8.6 | 1,223.5% | |
Current ratio | x | 6.4 | 1.1 | 554.3% | |
Inventory Days | Days | 8 | 91 | 9.2% | |
Debtors Days | Days | 842 | 96 | 878.2% | |
Net fixed assets | Rs m | 51,128 | 553,293 | 9.2% | |
Share capital | Rs m | 531 | 4,170 | 12.7% | |
Net worth | Rs m | 127,671 | 1,881,695 | 6.8% | |
Long term debt | Rs m | 0 | 866,172 | 0.0% | |
Total assets | Rs m | 148,565 | 3,871,297 | 3.8% | |
Interest coverage | x | 1,209.5 | 9.8 | 12,307.7% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.5 | 0.4 | 119.5% | |
Return on assets | % | 12.3 | 3.6 | 342.0% | |
Return on equity | % | 14.3 | 5.6 | 254.0% | |
Return on capital | % | 18.6 | 4.9 | 376.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 24,597 | 269,933 | 9.1% | |
From Investments | Rs m | -27,076 | -95,648 | 28.3% | |
From Financial Activity | Rs m | -7,972 | -323,803 | 2.5% | |
Net Cashflow | Rs m | -10,451 | -149,518 | 7.0% |
Compare DIVIS LABORATORIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare DIVIS LABORATORIES With: SHAMROCK IND MESCO PHARMA ANG LIFESCIENCES INDIA GUJ.THEMIS. MEDICAMEN BI
After opening the negative note, Indian share markets Slipped further as the session progressed and ended the day weak.